{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:07:42Z","timestamp":1761919662075},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,1,13]],"date-time":"2013-01-13T00:00:00Z","timestamp":1358035200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s10096-012-1799-z","type":"journal-article","created":{"date-parts":[[2013,1,12]],"date-time":"2013-01-12T06:18:37Z","timestamp":1357971517000},"page":"745-754","source":"Crossref","is-referenced-by-count":28,"title":["Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4"],"prefix":"10.1007","volume":"32","author":[{"given":"K.","family":"Domagalski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Paw\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tretyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Halota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pilarczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Smukalska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Linkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Grzybowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,1,13]]},"reference":[{"issue":"1","key":"1799_CR1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1586\/egh.09.76","volume":"4","author":"P Jara","year":"2010","unstructured":"Jara P, Hierro L (2010) Treatment of hepatitis C in children. Expert Rev Gastroenterol Hepatol 4(1):51\u201361","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"1799_CR2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1478-3231.2009.02145.x","volume":"30","author":"LT Yeung","year":"2010","unstructured":"Yeung LT, Roberts EA (2010) Current issues in the management of paediatric viral hepatitis. Liver Int 30(1):5\u201318","journal-title":"Liver Int"},{"issue":"9","key":"1799_CR3","first-page":"1057","volume":"15","author":"D Serranti","year":"2011","unstructured":"Serranti D, Buonsenso D, Ceccarelli M, Gargiullo L, Ranno O, Valentini P (2011) Pediatric hepatitis C infection: to treat or not to treat\u2026what\u2019s the best for the child? Eur Rev Med Pharmacol Sci 15(9):1057\u20131067","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"1799_CR4","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/hep.22543","volume":"48","author":"H Shirakawa","year":"2008","unstructured":"Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, Ichijo T, Yoshizawa K, Kiyosawa K, Tanaka E; Nagano Interferon Treatment Research Group (2008) Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 48(6):1753\u20131760","journal-title":"Hepatology"},{"issue":"10","key":"1799_CR5","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00535-009-0126-7","volume":"44","author":"S Maekawa","year":"2009","unstructured":"Maekawa S, Enomoto N (2009) Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol 44(10):1009\u20131015","journal-title":"J Gastroenterol"},{"issue":"9","key":"1799_CR6","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/j.1478-3231.2010.02283.x","volume":"30","author":"T Asselah","year":"2010","unstructured":"Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P (2010) Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 30(9):1259\u20131269","journal-title":"Liver Int"},{"issue":"4","key":"1799_CR7","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2008.07.013","volume":"49","author":"A Kau","year":"2008","unstructured":"Kau A, Vermehren J, Sarrazin C (2008) Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 49(4):634\u2013651","journal-title":"J Hepatol"},{"issue":"7262","key":"1799_CR8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399\u2013401","journal-title":"Nature"},{"issue":"4","key":"1799_CR9","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","volume":"138","author":"A Rauch","year":"2010","unstructured":"Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, G\u00fcnthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, M\u00fcllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138(4):1338\u20131345","journal-title":"Gastroenterology"},{"issue":"10","key":"1799_CR10","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, M\u00fcller T, Bahlo M, Stewart GJ, Booth DR, George J (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41(10):1100\u20131104","journal-title":"Nat Genet"},{"issue":"10","key":"1799_CR11","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41(10):1105\u20131109","journal-title":"Nat Genet"},{"issue":"1","key":"1799_CR12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","volume":"139","author":"AJ Thompson","year":"2010","unstructured":"Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG (2010) Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139(1):120\u2013129.e18","journal-title":"Gastroenterology"},{"issue":"2","key":"1799_CR13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/INF.0b013e318159836c","volume":"27","author":"P Jara","year":"2008","unstructured":"Jara P, Hierro L, de la Vega A, D\u00edaz C, Camarena C, Frauca E, Mi\u00f1os-Bartolo G, D\u00edez-Dorado R, de Guevara CL, Larrauri J, Rueda M (2008) Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 27(2):142\u2013148","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"1799_CR14","first-page":"CR616","volume":"16","author":"M Paw\u0142owska","year":"2010","unstructured":"Paw\u0142owska M, Pilarczyk M, Halota W (2010) Virologic response to treatment with Pegylated Interferon alfa-2b and Ribavirin for chronic hepatitis C in children. Med Sci Mon 16(12):CR616\u2013CR621","journal-title":"Med Sci Mon"},{"issue":"2","key":"1799_CR15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1053\/j.gastro.2010.10.047","volume":"140","author":"KB Schwarz","year":"2011","unstructured":"Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, Rosenthal P, Mohan P, Balistreri WF, Narkewicz MR, Smith L, Lobritto SJ, Rossi S, Valsamakis A, Goodman Z, Robuck PR, Barton BA; Peds-C Clinical Research Network (2011) The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 140(2):450\u2013458.e1","journal-title":"Gastroenterology"},{"issue":"6","key":"1799_CR16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jhep.2010.01.028","volume":"52","author":"EM Sokal","year":"2010","unstructured":"Sokal EM, Bourgois A, St\u00e9phenne X, Silveira T, Porta G, Gardovska D, Fischler B, Kelly D (2010) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 52(6):827\u2013831","journal-title":"J Hepatol"},{"issue":"4","key":"1799_CR17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jhep.2010.01.016","volume":"52","author":"S Wirth","year":"2010","unstructured":"Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, Shelton M, Kerkar N, Galoppo M, Pedreira A, Rodriguez-Baez N, Ciocca M, Lachaux A, Lacaille F, Lang T, Kullmer U, Huber WD, Gonzalez T, Pollack H, Alonso E, Broue P, Ramakrishna J, Neigut D, Valle-Segarra AD, Hunter B, Goodman Z, Xu CR, Zheng H, Noviello S, Sniukiene V, Brass C, Albrecht JK (2010) High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 52(4):501\u2013507","journal-title":"J Hepatol"},{"issue":"2","key":"1799_CR18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S1665-2681(19)31654-0","volume":"9","author":"J Al Ali","year":"2010","unstructured":"Al Ali J, Owayed S, Al-Qabandi W, Husain K, Hasan F (2010) Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. Ann Hepatol 9(2):156\u2013160","journal-title":"Ann Hepatol"},{"issue":"9","key":"1799_CR19","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s12098-009-0187-x","volume":"76","author":"TY Ghaffar","year":"2009","unstructured":"Ghaffar TY, El Naghy S, El Sebaie H, El Monaiery M, Ghaffar AY (2009) Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection. Indian J Pediatr 76(9):895\u2013898","journal-title":"Indian J Pediatr"},{"issue":"4","key":"1799_CR20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cgh.2010.07.019","volume":"9","author":"AF St\u00e4ttermayer","year":"2011","unstructured":"St\u00e4ttermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, Zinober K, Datz C, Maieron A, Dulic-Lakovic E, Kessler HH, Steindl-Munda P, Strasser M, Krall C, Ferenci P (2011) Impact of IL28B genotype on the early and sustained virologic response in treatment-na\u00efve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 9(4):344\u2013350.e2","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"1799_CR21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gon\u00e7ales FL Jr, H\u00e4ussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347(13):975\u2013982","journal-title":"N Engl J Med"},{"issue":"7","key":"1799_CR22","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1053\/j.gastro.2010.02.009","volume":"138","author":"JJ McCarthy","year":"2010","unstructured":"McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, Tillmann HL, Muir AJ, McHutchison JG (2010) Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138(7):2307\u20132314","journal-title":"Gastroenterology"},{"key":"1799_CR23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0168-8278(11)61331-7","volume":"53","author":"L Hierro","year":"2011","unstructured":"Hierro L, Alvarez L, Andueza S, Gordo-Giralt R, Lledin D, Camarena C, de la Vega A, Mu\u00f1oz-Bartolo G, Frauca E, Diaz C, Jara P (2011) Influence of IL28B gene polymorphisms on sustained response to peginterferon plus ribavirin in children with chronic hepatitis C. J Hepatol 53:524","journal-title":"J Hepatol"},{"issue":"7265","key":"1799_CR24","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O\u2019Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265):798\u2013801","journal-title":"Nature"},{"issue":"6","key":"1799_CR25","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/hep.24298","volume":"53","author":"A Ruiz-Extremera","year":"2011","unstructured":"Ruiz-Extremera A, Mu\u00f1oz-G\u00e1mez JA, Salmer\u00f3n-Ruiz MA, de Rueda PM, Quiles-P\u00e9rez R, Gila-Medina A, Casado J, Bel\u00e9n Mart\u00edn A, Sanjuan-Nu\u00f1ez L, Carazo A, Pav\u00f3n EJ, Ocete-Hita E, Le\u00f3n J, Salmer\u00f3n J (2011) Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 53(6):1830\u20131838","journal-title":"Hepatology"},{"issue":"6","key":"1799_CR26","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","volume":"361","author":"JG McHutchison","year":"2009","unstructured":"McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team (2009) Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361(6):580\u2013593","journal-title":"N Engl J Med"},{"issue":"5","key":"1799_CR27","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/hep.20661","volume":"41","author":"S Wirth","year":"2005","unstructured":"Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, Wintermeyer P, Jenke A (2005) Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 41(5):1013\u20131018","journal-title":"Hepatology"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-012-1799-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-012-1799-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-012-1799-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T20:35:33Z","timestamp":1644093333000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-012-1799-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,13]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["1799"],"URL":"https:\/\/doi.org\/10.1007\/s10096-012-1799-z","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,13]]}}}